Overview

Bioequivalence of Adapalene Topical Gel in Patients With Acne Vulgaris

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to evaluate the efficacy and safety of the test formulation of adapalene gel 0.1% (PLIVA Research & Development Ltd.) as compared to the already marketed formulation, Differin® (adapalene 0.1%) topical gel (Galderma Laboratories) in patients with acne vulgaris.
Phase:
Phase 1
Details
Lead Sponsor:
Teva Pharmaceuticals USA
Treatments:
Adapalene